Search En menu en ClientConnect
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages

    Signature(s)

    Amount
    € 100,000,000
    Countries
    Sector(s)
    Finland : € 100,000,000
    Industry : € 100,000,000
    Signature date(s)
    2/12/2021 : € 100,000,000
    Link to source

    Summary sheet

    Release date
    6 December 2021
    Status
    Reference
    Signed | 02/12/2021
    20210183
    Project name
    Promoter - financial intermediary
    ORION - CORE THERAPEUTIC II
    ORION OYJ
    Proposed EIB finance (Approximate amount)
    Total cost (Approximate amount)
    EUR 100 million
    EUR 434 million
    Location
    Sector(s)
    Description
    Objectives

    Research, development and innovation (RDI) investments in core therapeutic areas in 2021-2023.

    The project supports the Promoter's investments in pharmaceutical research and development (R&D). The investments are expected to facilitate the development of innovative medicinal products, whilst enabling the Promoter's competitiveness and growth.

    Additionality and Impact

    The promoter is a European pharmaceutical company continuously developing new drugs and treatment methods. The core therapy areas of R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. In addition to its own RDI capabilities, the promoter has developed a well-established network of collaborations with universities, research institutions and reputed industry partners. Companies producing innovative high-quality products are key drivers of economic growth, productivity and social protection, and generally a source of high value-added employment. By financing the project, EIB supports Orion's high quality R&D activities, and thus contributing to Europe's industrial competitiveness and economic growth. Orion's commitment to R&D will help to maintain highly skilled staff engaged in R&D activities in Europe.

     

    The EIB support to this operation is expected to provide tangible value-added benefit, positively contributing to the promoter's R&D investments by lowering the associated cost of financing and offering loan maturity beyond the tenor usually offered by commercial banks.

    Environmental aspects
    Procurement

    The project mainly concerns investments in R&D that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under the Directive 2014/52/EU amending the EIA Directive 2011/92/EU. Full environmental details will be verified during the appraisal.

    The Promoter is a private company not operating in the utilities sector and not having the status of a contracting authority. Thus, the project is not covered by the EU Directives on procurement. However, the Promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services will verify details during the project due diligence.

    Link to source

    Disclaimer

    Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
    They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

    Documents

    Environmental and Social Data Sheet (ESDS) - ORION - CORE THERAPEUTIC II
    Publication Date
    22 Dec 2021
    Document language
    Main Topic
    Lending
    Document Number
    141079088
    Document Focus
    Environmental Information
    Project Number
    20210183
    Sector(s)
    Regions
    Countries
    Publicly available
    Download now

    News & Stories

    General enquiries and comments

    The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
    Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
    Alternatively, the EIB can be contacted through its external offices.
    Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

    Media enquiries

    Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

    Complaints mechanism

    Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

    Zero tolerance against fraud and corruption

    The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.

    Related publications